injectable glp 1 agonist GLP-1s: What They Are and How They Work GLP-1 Medications: Everything You Need

Journal of Medicinal Chemistry

Our review of the clinical trial pipeline reveals 39 new GLP-1 drugs in development from 34 companies, with only seven among the top 20 pharmaceutical companies

GLP-1R reduces oxidative damage accumulation by modulating autophagy-related proteins and scavenging damaged mitochondria while increasing superoxide dismutase (SOD) and glutathione peroxidase activities, reducing the generation of lipid peroxidation products, inhibiting the NF-B signaling pathway, and decreasing proinflammatory factor expression to reduce neuroinflammation (Ma et al., 2018

The second group included individuals who started and continued either a GLP-1 receptor agonist or SGLT-2 inhibitor for the first time between January 1, 2013, and December 31, 2020